Detalhe da pesquisa
1.
Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
J Natl Compr Canc Netw
; 21(6): 609-616.e4, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37308126
2.
The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis.
Value Health
; 26(12): 1697-1710, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37741446
3.
US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER).
Genet Med
; 24(1): 238-244, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34906461
4.
Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings.
J Genet Couns
; 31(1): 130-139, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34231930
5.
Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes.
J Genet Couns
; 31(6): 1394-1403, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35900261
6.
Private payer coverage policies for ApoE-e4 genetic testing.
Genet Med
; 23(4): 614-620, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33420342
7.
Laboratory business models and practices: implications for availability and access to germline genetic testing.
Genet Med
; 23(9): 1681-1688, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958748
8.
Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS).
Genet Med
; 22(2): 283-291, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31501586
9.
Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.
J Natl Compr Canc Netw
; 18(7): 866-872, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32634780
10.
Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Value Health
; 23(5): 540-550, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32389218
11.
Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
Value Health
; 23(5): 551-558, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32389219
12.
Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited.
Genet Med
; 21(1): 152-160, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29997388
13.
Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive?
Genet Med
; 20(1): 165, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29261179
14.
Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial.
Genet Med
; 20(12): 1544-1553, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29565423
15.
Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening.
Genet Med
; 19(5): 559-567, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27657682
16.
Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research.
Genet Med
; 19(10): 1081-1091, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28406488
17.
Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
J Natl Compr Canc Netw
; 15(2): 219-228, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28188191
18.
"What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.
Value Health
; 20(1): 47-53, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28212968
19.
Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
Value Health
; 20(1): 40-46, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28212967
20.
EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
Int J Technol Assess Health Care
; 33(4): 534-540, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29065945